News & Events

Probiodrug to attend and present at International Conferences in April 2018

HALLE (SAALE), Germany, 10 April 2018 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that […]

Probiodrug reports full year 2017 financial results

PQ912 delivers positive pharmacodynamic and efficacy results in a Phase 2a study in early stage AD patients – data presented at CTAD, Boston, November 2017 PQ912 Phase […]

Probiodrug AG to Publish its Full Year 2017 Results on 3 April 2018

HALLE (SAALE), Germany, 27 March 2018 – Probiodrug AG (Euronext Amsterdam: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), will publish […]

Probiodrug to present at 255th ACS National Meeting & Exposition

The Inhibition of Glutaminyl Cyclase as a New Concept for the Treatment of Alzheimer’s Disease: PQ912, the First-In-Class QC-Inhibitor in Clinical Development for AD   HALLE […]

Probiodrug to attend and present at International Conferences in March 2018

HALLE (SAALE), Germany, 27 February 2018 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that the company […]

Probiodrug to attend and present at upcoming international conferences

HALLE (SAALE), Germany, 23 January 2018 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that the company […]

Probiodrug to attend and present at international conferences in January 2018

HALLE (SAALE), Germany, 14 December 2017 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that the company […]

Probiodrug and Crossbeta Biosciences extend their strategic partnership in the field of Alzheimer’s disease biomarkers

HALLE (SAALE), Germany, UTRECHT, The Netherlands, 5 December 2017 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease […]

Probiodrug reports Third Quarter 2017 Business Update

HALLE (SAALE), Germany, 30 November 2017 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), today announces […]